Ablative Solutions, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$286Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
179clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $65K
2020 $40K
2021 $92K
2022 $74K
2023 $15K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Specialties it works with most

Cardiovascular Disease $177K
Interventional Cardiology $40K
Internal Medicine $2,484
Nephrology (Internal Medicine) $2,301
Family Medicine $1,385
Ophthalmology $717

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Gregg Stone New York, NY Cardiovascular Disease $168,039.79
Michael Weber West Islip, NY $59,430.66
David Kandzari Atlanta, GA Interventional Cardiology $34,603.33
Maurice Buchbinder Encinitas, CA Cardiovascular Disease $2,415.24
Vasilios Papademetriou Washington, DC Cardiovascular Disease $1,566.59
Shukri David Southfield, MI Interventional Cardiology $1,024.03
Amir Kaki Detroit, MI Interventional Cardiology $1,010.48
Asif Ali Houston, TX Cardiovascular Disease $551.56
David Lee Stanford, CA Interventional Cardiology $538.24
Thomas Lalonde St Clair Shores, MI Cardiovascular Disease $479.56

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.